hier sind die News (englisch) bezüglich der Auswertung der Konferenz:
Biophan Technologies to Participate in yet2.com Conference; Boston Conference Will Focus On Acquiring New Technologies
ROCHESTER, N.Y., Mar 17, 2004 (BUSINESS WIRE) -- Biophan Technologies, Inc.
(OTCBB: BIPH) an innovator, developer and marketer of MRI-related and other
advanced biomedical technology, announced today that it will present at
yet2.com`s conference, " Proudly Found Elsewhere: Technology Acquisition as a
Leading Edge Strategy for R&D." The conference will address best practices for
acquiring key new technologies from the outside to speed internal product
development, and will take place March 22-23, 2004, at The World Trade Center in
Boston, MA.
The Conference provides an executive briefing for Chief Executive Officers,
Chief Technology Officers, R&D Executives, Strategic Intellectual Asset
Managers, Licensing Executives, and Business Managers
Biophan will be presenting to and interfacing with an audience of technology
managers from many of the largest and most successful companies in the world and
presenting along with inventor-entrepreneurs such as Dean Kamen and Kevin
Rivette.
Mr. Weiner will speak on Biophan`s genesis from an idea of Wilson Greatbatch* to
make future pacemakers safe for MRI, to a company with over fifty patents
pending, issued, or allowed, covering multiple solutions to allow all biomedical
devices to be MRI safe and image compatible.
*Mr. Greatbatch is the inventor of the first successful pacemaker, licensed to
Medtronic (NYSE:MDT), and he developed the technology for the lithium iodine
battery used in most implantable devices. He is founder of Wilson Greatbatch
Technologies, Inc. (NYSE:GB).
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge technologies used to make
biomedical devices--such as cardiac pacemakers, surgical and diagnostic
tools--safe and compatible with magnetic resonance imaging (MRI) equipment. The
technology is also being used to create enhanced MRI contrast agents. Committed
to growth through innovation and developmental leadership, Biophan and its
licensors have four issued U.S. patents and over fifty patents pending, in areas
including nanomagnetic particle coatings, radio frequency filters, polymer
composites, and photonics. Biophan`s technology will help realize its goal of
one day making all biomedical devices capable of safely and successfully working
with MRI. For more information, please visit www.biophan.com.
About yet2.com
yet2.com Inc and its online marketplace were founded in 1999 to promote
technology licensing and transfer, with joint investment from Siemens, Bayer,
Honeywell, Dupont, Procter & Gamble, Caterpillar, and NTT DoCoMo. The company
has offices in the United States, Europe, and Japan. Its clientele consists of
over a quarter of the Fortune 1000. For more information, visit
www.yet2.com.
About the yet2.com Conference
For more information on the yet2.com conference, please visit
www.yet2.com/app/global/en/html/exec_briefing_6.html.
Safe Harbor Statement:
Certain statements included in this press release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results could differ materially from such statements expressed or implied
herein as a result of a variety of factors including, but not limited to: the
development of the Company`s MRI technologies; the approval of the Company`s
patent applications; the successful implementation of the Company`s research and
development programs; the acceptance by the market of the Company`s products;
competition and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in the
Company`s periodic filings with the Securities and Exchange Commission (the
" SEC" ). As a result, this press release should be read in conjunction with the
Company`s periodic filings with the SEC. The forward-looking statements
contained herein are made only as of the date of this press release, and the
Company undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
SOURCE: Biophan Technologies, Inc.
CONTACT: Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Michael Weiner, 585-214-2441
or
yet2.com
Elizabeth Dobbs, 617-557-3800
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.